CXCR2 inhibition in G-MDSCs enhances CD47 blockade for melanoma tumor cell clearance
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2318534121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Allison Banuelos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305. Hauptthemen laut MEDLINE: Melanoma, Experimental, Myeloid-Derived Suppressor Cells. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
The use of colony-stimulating factor-1 receptor (CSF1R) inhibitors has been widely explored as a strategy for cancer immunotherapy due to their robust depletion of tumor-associated macrophages (TAMs). While CSF1R blockade effectively eliminates TAMs from the solid tumor microenvironment, its clinical efficacy is limited. Here, we use an inducible CSF1R knockout model to investigate the persistence of tumor progression in the absence of TAMs. We find increased frequencies of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the bone marrow, throughout circulation, and in the tumor following CSF1R deletion and loss of TAMs. We find that G-MDSCs are capable of suppressing macrophage phagocytosis, and the elimination of G-MDSCs through CXCR2 inhibition increases macrophage capacity for tumor cell clearance. Further, we find that combination therapy of CXCR2 inhibition and CD47 blockade synergize to elicit a significant anti-tumor response. These findings reveal G-MDSCs as key drivers of tumor immunosuppression and demonstrate their inhibition as a potent strategy to increase macrophage phagocytosis and enhance the anti-tumor efficacy of CD47 blockade in B16-F10 melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305.
- Ludwig Center for Cancer Stem Cell Research and Medicine, Stanford University, Stanford, CA 94305.
- Hematopoietic Stem Cell Biology and Medical Innovation (HSCBMI), Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0047, Japan.
- Department of Pathology, Stanford University, Stanford, CA 94305.
ORCID-Profile: Allison Zhang, Irving L Weissman
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Banuelos, A., Zhang, A., Berouti, H., Baez, M., Yılmaz, L., Georgeos, N., Marjon, K. D., Miyanishi, M., & Weissman, I. L. (2024). CXCR2 inhibition in G-MDSCs enhances CD47 blockade for melanoma tumor cell clearance. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2318534121
Vancouver
Banuelos A, Zhang A, Berouti H, Baez M, Yılmaz L, Georgeos N, et al. CXCR2 inhibition in G-MDSCs enhances CD47 blockade for melanoma tumor cell clearance. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2318534121
BibTeX
@article{Banuelos2024,
author = {Banuelos, Allison and Zhang, Allison and Berouti, Hala and Baez, Michelle and Yılmaz, Leyla and Georgeos, Nardin and Marjon, Kristopher D and Miyanishi, Masanori and Weissman, Irving L},
title = {CXCR2 inhibition in G-MDSCs enhances CD47 blockade for melanoma tumor cell clearance},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2318534121}
}
EUVIMED